Botanical species · safety record

Acalypha indica

The EFSA Compendium of Botanicals holds 12 constituent measurements and 1 adverse-effect record for Acalypha indica. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Acalypha indica L.

12Constituent measurements

1Safety records

6Cited sources

13Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 13 licensed products naming Acalypha indica as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Plant

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Acalyphin	Stem / stalk	Solvent extraction	0.033 Percent	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Acalyphin	Roots and other underground parts	Solvent extraction	0.055 Percent	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Acalyphin	Leaves	Solvent extraction	—	—	Resolve DOI
Acalyphin	Aerial part of plants	Solvent extraction	0.35 Percent	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Alkaloids	Aerial part of plants	Solvent extraction	—	Phytochemical screening	Resolve DOI
Anthraquinones	Leaves	Solvent extraction	—	—	Resolve DOI
Cyanogenic glycosides	Leaves	Solvent extraction	—	—	Resolve DOI
Piperidine alkaloids	Leaves	Solvent extraction	—	—	Resolve DOI
Tannins	Aerial part of plants	Solvent extraction	—	Phytochemical screening	Resolve DOI
Dicumarol	Leaves	Solvent extraction	103.7 Milligram/kilogram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Saponins	Live plants	Solvent extraction	—	Phytochemical screening	No resolvable identifier
Tannins	Live plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Reproductive	Uterus	Live plants	Solvent extraction	Rat (as animal)	Reproduction toxicity	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Kumar, D., Kumar, A., Prakash, O. Potential antifertility agents from plants: A comprehensive review. Journal of ethnopharmacology, 2012, vol. 140, no. 1, p. 1-32. DOI
Ma, YT., Chuang, JI., Lin, JH., Hsu, FL. Phenolics from Acalypha indica. Journal of the chinese chemical society, 1997, vol. 44, no. 5, p. 499-502.
Takle, V.V., Savad, R.V., Kandalkar, A.M., Akarte, A.M., Patel, A.M. Pharmacognostic and phytochemical investigations of aerial parts of Acalypha indica Linn.. Pharmacognosy journal, 2011, vol. 3, no. 21, p. 33-35. DOI
Pandith, Javid Iqbal. Phytochemical screening of certain plant species of Agra city.. Journal of drug delivery and therapeutics, 2012, vol. 2, no. 4, p. 135-138.
Murugan, P.S., Selvam, G.S. Identification and quantification of phytocompounds in Acalypha indica leaves. International journal of pharma and bio sciences, 2015, vol. 6, no. 2, p. P11-P21.
Hungeling, Monika., Lechtenberg, Matthias., Fronczek, Frank R., Nahrstedt, Adolf. Cyanogenic and non-cyanogenic pyridone glucosides from Acalypha indica (Euphorbiaceae) . Phytochemistry, 2009, vol. 70, no. 2, p. 270-277. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature